By Fineline Cube 
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at the 2025 ASCO Annual Meeting. The findings highlight the potential of JSKN003 across multiple indications.
Clinical Trial Results
The JSKN003-101 and JSKN003-102 studies, conducted in Australia and China, assessed the drug in patients with platinum-resistant recurrent epithelial ovarian cancer (PROC), HER2-positive breast cancer, and gastrointestinal tumors with high HER2 expression. Results showed high objective response rates (ORR) and disease control rates (DCR) across different indications and HER2 expression levels. The safety profile was favorable, with most adverse events being mild to moderate, and no treatment-related deaths reported.
JSKN003 Mechanism and Development
JSKN003 is a HER2 bispecific epitope antibody-drug conjugate (ADC) designed to enhance binding affinity by targeting two distinct HER2 epitopes. This improves drug internalization and bystander killing effects. JSKN003 is currently undergoing multiple Phase III clinical trials in China, covering HER2-positive breast cancer, HER2-low breast cancer, and PROC.-Fineline Info & Tech